Here is a breakdown of the information Alcon presented to its investors. Alcon, the global leader in eye care, is renowned for its comprehensive range of products addressing conditions like cataracts, ...

Analyst Jeff Johnson of Robert W. Baird maintained a Buy rating on Alcon (ALC – Research Report), retaining the price target of $110.00.

Shares were recently down 6.6% to $86.23 Tuesday. Alcon, whose products include contact lenses and eye drops, said sales were helped by factors including product innovation, such as toric and ...

Alcon, the global eyecare company with manufacturing and research facilities in Berks County, reported third quarter results ...

Alcon, whose biggest market is the U.S. making up nearly a half of its revenue, said it expected annual net sales to grow by ...

Alcon Inc (ALC) reports strong international growth and prepares for new product launches despite facing competitive pressures in the US market.

Yesterday, Alcon was alerted that our third quarter earnings press ... s local presence and established capabilities will help maximize the value of our dry eye products and procedural eye drops, ...

Third-quarter 2024 sales of $2.4 billion, up 6% on a reported and constant currency1 (cc) basis Third-quarter 2024 diluted EPS of $0.53, up 29%, or 32% cc; core diluted EPS2 of $0.81, up 23% ...

Alcon, Inc. ALC delivered core earnings per share (EPS) of 81 cents for the third quarter of 2024, up 22.7% from the year-ago ...

The new director at the FDA overseeing medical devices will confront criticisms about hasty approvals as she ushers in ...